CA3187760A1 - Replication stress pathway agent compositions and methods for treating cancer - Google Patents

Replication stress pathway agent compositions and methods for treating cancer

Info

Publication number
CA3187760A1
CA3187760A1 CA3187760A CA3187760A CA3187760A1 CA 3187760 A1 CA3187760 A1 CA 3187760A1 CA 3187760 A CA3187760 A CA 3187760A CA 3187760 A CA3187760 A CA 3187760A CA 3187760 A1 CA3187760 A1 CA 3187760A1
Authority
CA
Canada
Prior art keywords
ecdna
tumor
cells
treatment
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3187760A
Other languages
English (en)
French (fr)
Inventor
Christian Hassig
Ryan Hansen
Snezana Milutinovic
Jason Christiansen
Zachary HORNBY
Sudhir CHOWDHRY
Anthony Celeste
Kristen Turner
Deepti WILKINSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boundless Bio Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3187760A1 publication Critical patent/CA3187760A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3187760A 2020-08-12 2021-08-11 Replication stress pathway agent compositions and methods for treating cancer Pending CA3187760A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063064555P 2020-08-12 2020-08-12
US63/064,555 2020-08-12
US202163168120P 2021-03-30 2021-03-30
US63/168,120 2021-03-30
PCT/US2021/045556 WO2022035970A1 (en) 2020-08-12 2021-08-11 Replication stress pathway agent compositions and methods for treating cancer

Publications (1)

Publication Number Publication Date
CA3187760A1 true CA3187760A1 (en) 2022-02-17

Family

ID=80247345

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3187760A Pending CA3187760A1 (en) 2020-08-12 2021-08-11 Replication stress pathway agent compositions and methods for treating cancer

Country Status (11)

Country Link
US (3) US11547711B2 (enExample)
EP (1) EP4196614A4 (enExample)
JP (1) JP2023537600A (enExample)
KR (1) KR20230098134A (enExample)
CN (1) CN116368243A (enExample)
AU (1) AU2021325905A1 (enExample)
BR (1) BR112023002453A2 (enExample)
CA (1) CA3187760A1 (enExample)
MX (1) MX2023001717A (enExample)
TW (1) TW202221118A (enExample)
WO (1) WO2022035970A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023002453A2 (pt) 2020-08-12 2023-05-02 Boundless Bio Inc Composições de agente de via de estresse de replicação e métodos para tratar câncer
EP4278185A1 (en) * 2021-01-18 2023-11-22 GBG Forschungs GmbH Method for predicting the response to cdk4/6 inhibitor therapy in cancer patients
EP4347582A4 (en) 2021-05-27 2025-05-07 Boundless Bio, Inc. CHECKPOINT KINASE-1 INHIBITORS AND USES THEREOF
CN114835640B (zh) * 2022-05-24 2024-02-13 中国药科大学 成纤维细胞生长因子受体抑制剂、制备方法及应用
EP4587026A1 (en) * 2022-09-15 2025-07-23 Recurium IP Holdings, LLC Combinations
CN116083576B (zh) * 2022-12-07 2024-01-30 上海市临床检验中心 一种基于CRISPR/Cas12a的KRAS热点基因突变检测系统和方法
CN116445411A (zh) * 2023-02-01 2023-07-18 复旦大学附属华山医院 一种小鼠结肠癌索托拉西布耐药细胞株及制备方法与应用
EP4770642A2 (en) * 2023-09-01 2026-07-08 Boundless Bio, Inc. Ribonucleotide reductase (rnr) compositions and methods of use
WO2025184572A1 (en) * 2024-03-01 2025-09-04 Zeno Management, Inc. Wee1 inhibitor combination therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS567007A (en) 1979-06-29 1981-01-24 Toshiba Corp Coating film thickness measuring apparatus
WO2018136837A1 (en) * 2017-01-20 2018-07-26 The Jackson Laboratory A method of targeting patient-specific oncogenes in extrachromosomal dna to treat glioblastoma
MX2019012176A (es) * 2017-04-10 2020-02-19 Sierra Oncology Inc Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral.
US11193164B2 (en) * 2017-05-24 2021-12-07 The Regents Of The University Of California Methods of diagnosing and treating cancer targeting extrachromosomal DNA
AU2018278336A1 (en) * 2017-06-01 2020-01-16 Crt Pioneer Fund Lp Biomarkers and patient selection strategies
US20210047693A1 (en) * 2017-11-15 2021-02-18 The Regents Of The University Of California Methods of treating extrachromosomal dna expressing cancers
JP2021514979A (ja) * 2018-02-26 2021-06-17 シエラ オンコロジー， インコーポレイテッド Ｃｈｋ１阻害剤を含む癌の治療方法
WO2020123530A1 (en) * 2018-12-10 2020-06-18 The Regents Of The University Of California Compositions and methods for modulating transcriptional activity of amplified oncogenes contained on extrachromosomal dna
EP3966323A4 (en) * 2019-05-06 2024-04-24 The Regents Of The University Of Michigan Targeted therapy
BR112023002453A2 (pt) 2020-08-12 2023-05-02 Boundless Bio Inc Composições de agente de via de estresse de replicação e métodos para tratar câncer
EP4347582A4 (en) 2021-05-27 2025-05-07 Boundless Bio, Inc. CHECKPOINT KINASE-1 INHIBITORS AND USES THEREOF
KR20240101555A (ko) 2021-09-17 2024-07-02 바운드리스 바이오, 인크. 사이클릭 설폰아미드 리보뉴클레오타이드 환원효소(rnr) 억제제 및 이의 용도
EP4402134A4 (en) 2021-09-17 2025-10-15 Boundless Bio Inc SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND THEIR USES
US20230272485A1 (en) 2022-02-16 2023-08-31 Boundless Bio, Inc. Replication stress pathway agent compositions and methods for treating cancer

Also Published As

Publication number Publication date
US20220143022A1 (en) 2022-05-12
TW202221118A (zh) 2022-06-01
CN116368243A (zh) 2023-06-30
BR112023002453A2 (pt) 2023-05-02
WO2022035970A1 (en) 2022-02-17
US11547711B2 (en) 2023-01-10
US20230248728A1 (en) 2023-08-10
EP4196614A4 (en) 2024-12-18
MX2023001717A (es) 2023-04-13
US11642345B2 (en) 2023-05-09
US12246017B2 (en) 2025-03-11
EP4196614A1 (en) 2023-06-21
AU2021325905A1 (en) 2023-04-13
US20230078903A1 (en) 2023-03-16
JP2023537600A (ja) 2023-09-04
KR20230098134A (ko) 2023-07-03

Similar Documents

Publication Publication Date Title
US11642345B2 (en) Replication stress pathway agent compositions and methods for treating cancer
JP7536320B2 (ja) Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ
KR102845148B1 (ko) Her2 양성 암의 치료
Egloff et al. Improving response rates to EGFR‐targeted therapies for head and neck squamous cell carcinoma: candidate predictive biomarkers and combination treatment with Src inhibitors
Lopez et al. Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo
Liang et al. Expression and function analysis of mitotic checkpoint genes identifies TTK as a potential therapeutic target for human hepatocellular carcinoma
Takeda et al. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer
JP2022511498A (ja) Ｃｄｋ４／６阻害剤に耐性の癌を治療するための方法
Nokin et al. Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma
Huang et al. Small molecule inhibitors in adult high-grade glioma: from the past to the future
Gao et al. Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics
He et al. HDAC inhibitors target IRS4 to enhance anti‑AR therapy in AR‑positive triple‑negative breast cancer
US11957677B2 (en) Cancer treatment using FGFR inhibitors and PLK1 inhibitors
US20170196880A1 (en) Antitumor activity of multi-kinase inhibitors in triple negative breast cancer
US11179413B2 (en) Methods of treatment of cancer with reduced UBB expression
Kayser et al. Targeting the FLT3 mutation in acute myeloid leukaemia
US20260069596A1 (en) Use of plk1 inhibitor as monotherapy and in combination with cetuximab in treating ras wild-type colorectal cancer
US20260116962A1 (en) Plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancer
Glorieux et al. Combining radiotherapy with DNA repair inhibitors as novel treatment strategy for head and neck cancers
Selby et al. Management of Philadelphia Chromosome-positive Acute Lymphoblastic Leukaemia
WO2025117928A1 (en) Breast cancer treatment using pi3k inhibitor and cell cycle inhibitor
WO2025049904A1 (en) Egfr inhibitor for use in the treatment of lung cancer positive for an egfr exon 20 mutation
WO2024054898A1 (en) Onvansertib and parp inhibitor combination
WO2025240673A1 (en) Cancer treatment using akt inhibitors and plk1 inhibitors
Rudin Genetic and Epigenetic Determinants of Lung Cancer Subtype: Adenocarcinoma to Small Cell Conversion

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240802

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240802

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250801

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250801

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260206

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-1-6-B10-B12-B301 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO A REQUEST FOR EXAMINATION NOTICE

Effective date: 20260407

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260709